These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8117005)

  • 61. [Activated charcoal, laxatives, and mucilaginous agents against acute poisoning].
    Haffner J
    Tidsskr Nor Laegeforen; 1971 Dec; 91(35):2569-71. PubMed ID: 5171830
    [No Abstract]   [Full Text] [Related]  

  • 62. Comparison of charcoal and attapulgite as gastrointestinal sequestrants in acute drug ingestions.
    Atkinson JP; Azarnoff DL
    Clin Toxicol; 1971 Mar; 4(1):31-8. PubMed ID: 4328989
    [No Abstract]   [Full Text] [Related]  

  • 63. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
    Zhang D; Frost CE; He K; Rodrigues AD; Wang X; Wang L; Goosen TC; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):906-15. PubMed ID: 23386703
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prevention of chloroquine absorption by activated charcoal.
    Neuvonen PJ; Kivistö KT; Laine K; Pyykkö K
    Hum Exp Toxicol; 1992 Mar; 11(2):117-20. PubMed ID: 1349217
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Activated charcoal and the absorption of ferrous sulfate in rats.
    Gades NM; Chyka PA; Butler AY; Virgous CK; Mandrell TD
    Vet Hum Toxicol; 2003 Aug; 45(4):183-7. PubMed ID: 12882486
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adsorbent and cathartic inhibition of enteral drug absorption.
    Van de Graaff WB; Thompson WL; Sunshine I; Fretthold D; Leickly F; Dayton H
    J Pharmacol Exp Ther; 1982 Jun; 221(3):656-63. PubMed ID: 7086679
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders.
    Csako G; McGriff NJ; Rotman-Pikielny P; Sarlis NJ; Pucino F
    Ann Pharmacother; 2001 Dec; 35(12):1578-83. PubMed ID: 11793625
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease.
    Klein I; Danzi S
    Thyroid; 2003 Dec; 13(12):1127-32. PubMed ID: 14751033
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tablet formulation of levothyroxine is absorbed less well than powdered levothyroxine.
    Yamamoto T
    Thyroid; 2003 Dec; 13(12):1177-81. PubMed ID: 14751040
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of activated charcoal and magnesium citrate in the prevention of aspirin absorption in humans.
    Easom JM; Caraccio TR; Lovejoy FH
    Clin Pharm; 1982; 1(2):154-6. PubMed ID: 7185512
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Levothyroxine dosage and the limitations of current bioequivalence standards.
    Hennessey JV
    Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756
    [No Abstract]   [Full Text] [Related]  

  • 72. The emergence of levothyroxine as a treatment for hypothyroidism.
    Hennessey JV
    Endocrine; 2017 Jan; 55(1):6-18. PubMed ID: 27981511
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide.
    Neuvonen PJ; Kivistö K; Hirvisalo EL
    Br J Clin Pharmacol; 1988 Feb; 25(2):229-33. PubMed ID: 3358884
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches.
    Centanni M
    Endocrine; 2013 Feb; 43(1):8-9. PubMed ID: 23097095
    [No Abstract]   [Full Text] [Related]  

  • 75. Influence of charcoal on ciprofloxacin activity.
    Torre D
    Rev Infect Dis; 1988; 10(6):1231. PubMed ID: 3206065
    [No Abstract]   [Full Text] [Related]  

  • 76. The absorption of liquid levo-thyroxine is not significantly impaired by food intake.
    De Luca F
    Acta Biomed; 2016 Jan; 87(3):231-232. PubMed ID: 28112687
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Levothyroxine therapy.
    Liel Y
    Ann Intern Med; 1994 Apr; 120(7):619; author reply 619-20. PubMed ID: 8117005
    [No Abstract]   [Full Text] [Related]  

  • 78. [Primary hypothyroidism: Considerations for a rational use of levothyroxine therapy].
    Bros JA; Lluís PG; Cabot GL; Pedragós AC
    Med Clin (Barc); 2011 Feb; 136(5):207-14. PubMed ID: 19646718
    [No Abstract]   [Full Text] [Related]  

  • 79. Levothyroxine-cholestyramine interaction reemphasized.
    Harmon SM; Seifert CF
    Ann Intern Med; 1991 Oct; 115(8):658-9. PubMed ID: 1892339
    [No Abstract]   [Full Text] [Related]  

  • 80. Conditions and drugs interfering with thyroxine absorption.
    Liwanpo L; Hershman JM
    Best Pract Res Clin Endocrinol Metab; 2009 Dec; 23(6):781-92. PubMed ID: 19942153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.